Search Results for "amyloidosis"

Alnylam is committed to providing the healthcare community with balanced, accurate, and high-quality information about our science, therapeutic areas, and products.

More than one search term is recommended to yield the most relevant results. By searching, you confirm that your query is unsolicited.

For more information about our FDA-approved therapies, please see the Full Prescribing Information:

Effect of Patisiran on Polyneuropathy and Cardiomyopathy in Patients with Hereditary Transthyretin Mediated (hATTR) Amyloidosis with a V122I or T60A Variant: A Phase 4 Observational Study

Primary Results From APOLLO-B, A Phase 3 Study of Patisiran in Patients With Transthyretin-Mediated Amyloidosis With Cardiomyopathy

Alnylam Pharmaceuticals submitted a supplemental New Drug Application (sNDA) to the FDA for patisiran for the treatment of the cardiomyopathy of ATTR amyloidosis based on data from the APOLLO-B study. The FDA subsequently completed their review of the application in 2023 and issued a complete response letter (CRL).

HELIOS-A: 18 Month Exploratory Cardiac Results from the Phase 3 Study of Vutrisiran in Patients with Hereditary Transthyretin Mediated Amyloidosis

APOLLO-B, a Study of Patisiran in Patients with Transthyretin Cardiac Amyloidosis: Primary Long-term Results from the Open-label Extension Period

Patisiran Treatment for ATTR Cardiac Amyloidosis: 18-Month Results of the Phase 3 APOLLO-B Study

Baseline Characteristics of Patients with ATTR Amyloidosis Enrolled into the ConTTRibute Registry

Evaluation of Disease Progression in Patients with ATTR Amyloidosis with Cardiomyopathy Following Treatment with Patisiran: Post hoc Analysis of the APOLLO-B Study

Patisiran Global Open-Label Extension Study at 36 Months: Effect of Long-Term Treatment on Mortality and Ambulatory Function in Patients with hATTR Amyloidosis with Polyneuropathy

Real-World Treatment Patterns in Participants with Transthyretin Amyloidosis with Polyneuropathy Enrolled in the ConTTRibute Registry

Realizing the therapeutic potential of rapid knockdown of transthyretin via RNA interference in transthyretin amyloidosis

For further information regarding your request, please connect with us by reaching out to your local Medical Science Liaison or contacting our Medical Information team.